NCT03914859

Brief Summary

The main objective of this study is to highlight a relationship between exposure to PAHs, genotoxic effect biomarkers on spermatozoa and follicular cells, as well as embryonic quality and embryo implantation rates at a given time. IVF attempt. This study therefore analyzes the possibility of using this exposure biomarker as a reliable means of evaluating the quality of gametes in order to estimate the chances of success in IVF.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
220

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2019

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 11, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 16, 2019

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2022

Completed
Last Updated

April 16, 2019

Status Verified

April 1, 2019

Enrollment Period

2 years

First QC Date

April 11, 2019

Last Update Submit

April 11, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • expired CO

    The night before the IVF, a urine sample will be collected from both members of the couple, according to the protocol published by the team Partner 2. On the day of the IVF, a measurement of the exhaled CO rate will be carried out by the two members of the couple according to the recommendations of the manufacturer.

    72 hours

Study Arms (2)

Exposed

OTHER

Urinary level of 1-hydroxypyrene, the most sensitive biomarker of PAH exposure greater than 0.1 μmol / mol creatinine

Biological: IN VITRO FERTILIZATION

Not exposed

OTHER

Urinary level of 1-hydroxypyrene, the most sensitive marker of PAH exposure below 0.1 μmol / mol creatinine

Biological: IN VITRO FERTILIZATION

Interventions

Using exposure biomarker as a reliable means of evaluating gamete quality to estimate the chances of success in in vitro fertilization.

ExposedNot exposed

Eligibility Criteria

Age36 Years - 45 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Couples whose wife is under 36 and the man under 45 at the time of IVF
  • Regular cycles of 27 to 33 days in women
  • Management of classical IVF (without the use of micro-sperm injection)
  • st or 2nd attempt of IVF
  • Signature of informed consent by both partners of the couple
  • Affiliation to a social security scheme or equivalent for both partners of the couple.

You may not qualify if:

  • Refusal to participate in the study of one or both members of the couple
  • No fluency in French
  • History likely to alter the ovarian reserve, endometriosis
  • Uterine or systemic antecedents, likely to affect implantation
  • Andrological antecedents likely to alter fertilization rates
  • History of chemotherapy / radiotherapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assistance des Hôpitaux de Marseille

Marseille, 13354, France

RECRUITING

MeSH Terms

Conditions

Infertility

Interventions

Fertilization in Vitro

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Intervention Hierarchy (Ancestors)

Reproductive Techniques, AssistedReproductive TechniquesTherapeuticsInvestigative Techniques

Study Officials

  • EMILIE GARRIDO

    Assistance Publique Hopitaux De Marseille

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: The groups will be defined according to the urinary level of 1-hydroxypyrene, the most sensitive biomarker for PAH exposure. A threshold of 0.1 μmol / mol of creatinine was determined according to the INRS. It corresponds to the 90th percentile value for non-smokers not occupationally and nutritionally exposed. The reference value in the general population is \<0.51 μg / g creatinine, and in smokers \<0.3 μmol / mol creatinine.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 11, 2019

First Posted

April 16, 2019

Study Start

February 1, 2019

Primary Completion

February 1, 2021

Study Completion

February 1, 2022

Last Updated

April 16, 2019

Record last verified: 2019-04

Locations